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BACKGROUND: Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and 
 persistence with therapy. In SWOG S1202, patients with AIMSS who were treated with duloxetine, a serotonin norepinephrine reup-
take inhibitor, reported improvement in pain by 12 weeks compared with placebo. Based on the authors’ prior observation that 
 responses to pain interventions differ between obese and nonobese patients, the current study examined whether response to 
 duloxetine therapy differed by obesity status. METHODS: In SWOG S1202, a total of 299 AI-treated postmenopausal women with 
stage I to III (AJCC 7th Edition) breast cancer who developed new or worsening average pain were enrolled, randomized to duloxe-
tine or placebo, and treated for 12 weeks. Patient-reported outcomes were obtained at baseline and through 12 weeks. Patients were 
categorized into nonobese (body mass index [BMI] <30 kg/m2) or obese (BMI ≥30 kg/m2). The authors tested the interaction 
between intervention and obesity with respect to average pain at 12 weeks in the 289 eligible patients, using a P value of .05 to indicate 
statistical significance. RESULTS: In approximately 54% of evaluable patients with a BMI ≥30 kg/m2, the reduction in the mean aver-
age pain score between baseline and 12 weeks was statistically significantly greater for patients treated with duloxetine compared 
with those  receiving placebo (-2.73 vs -1.64 points; P = .003). Conversely, in the nonobese patients, the reduction in the mean aver-
age pain score was similar in the 2 cohorts (-2.46 vs -2.34 points; P = .75). The P value for interaction was .02, thereby meeting the 
threshold criteria of the current study. Similar findings were evident for other pain-related patient-reported outcomes. CONCLUSIONS: 
In this trial, obese patients with AIMSS obtained more analgesic benefit from duloxetine compared with nonobese patients. Additional 
studies are warranted to determine the biologic basis for these findings. Cancer 2019;125:2123-2129. © 2019 American Cancer Society. 
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INTRODUCTION
Although aromatase inhibitors (AIs) have been shown to reduce the risk of disease recurrence and mortality in 
 postmenopausal women with early-stage, hormone receptor-positive breast cancer,1 adherence to and persistence with 
therapy is limited by treatment-emergent toxicity.2,3 In particular, AI-associated musculoskeletal symptoms (AIMSS) 
occur in a substantial percentage of women undergoing AI therapy and contribute to the discontinuation of therapy in 
as much as 25% of treated patients.3
To the best of our knowledge, the mechanism underlying the development of AIMSS remains undefined. Several 
predictors of developing treatment-emergent symptoms have been identified, including age closer to menopause, higher 
body mass index (BMI), prior treatment with chemotherapy, and preexisting joint pain, although not all have been 
validated.3-5 Management options for AIMSS remain limited. However, randomized trials of a variety of interventions, 
including exercise, acupuncture, and duloxetine, have been conducted that have demonstrated modest improvements in 
AIMSS; substantial placebo effects also have been noted.6-8
Duloxetine is a serotonin-norepinephrine reuptake inhibitor that is used to treat mood disorders and chronic 
pain conditions. A large, double-blind, placebo-controlled trial of duloxetine for postmenopausal women with AIMSS 
examined change in average pain with 12 weeks of therapy (SWOG S1202).7 Average joint pain on a scale of 0 to 10 
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was found to be 0.82 points lower for those patients 
treated with  duloxetine compared with those treated 
with placebo (95% confidence interval, -1.24 to -0.40; 
P = .0002).
A randomized trial of omega-3 fatty acid (O3-FA) 
supplementation versus placebo was conducted by 
SWOG (SWOG S0927) that demonstrated significant 
improvements in worst pain, although the benefit was 
similar in both treatment arms.9 Recently, because of 
previously reported associations between obesity and 
inflammation as well as the anti-inflammatory effects 
of O3-FA supplementation,10-12 an exploratory analysis 
was conducted to examine the association between obe-
sity and response to O3-FA supplementation.13 O3-FA 
use was found to be associated with a significantly lower 
Brief Pain Inventory (BPI) worst pain score (range, 
0-10) at 24 weeks in patients with a BMI ≥30 kg/m2 
who were treated with O3-FA compared with placebo 
(4.36 vs 5.70; P = .02). In contrast, no such association 
was identified among patients with a BMI <30 kg/m2 
(5.27 vs 4.58; P = .28 [P for interaction, .05).
Based on the findings of this exploratory analysis 
in SWOG S0927, we hypothesized that this BMI effect 
was due to systemic inflammation, because inflamma-
tion is higher in the setting of obesity and O3-FAs have 
been shown to be anti-inflammatory. We were unsure 
whether a similar intervention effect would be observed 
in a trial of the treatment of patients with AIMSS using 
a drug with a different mechanism of action. Therefore, 
we  analyzed response to duloxetine versus placebo by 
BMI in patients enrolled on SWOG clinical trial S1202, 
hypothesizing that patterns of response would differ 
between obese and nonobese patients.
MATERIALS AND METHODS
Eligibility
SWOG trial S1202 (ClinicalTrials.gov identifier 
NCT01598298) was approved by the institutional  review 
boards of the participating institutions and  enrolled 
 patients between May 2013 and October 2015. All 
 patients provided written informed consent prior to 
protocol-directed procedures. A description of SWOG 
S1202, including study design and inclusion and ex-
clusion criteria (including a Consolidated Standards 
Of Reporting Trials [CONSORT] diagram), was pub-
lished previously.7 In brief, postmenopausal women with 
stage I to III (AJCC 7th Edition) hormone receptor- 
positive breast cancer who had been receiving AI 
therapy for at least 3 weeks and for ≤24 months 
and who developed new or worsened average joint pain 
measuring at least 4 on a scale of 0 to 10 on the BPI were 
enrolled.
Study Design
Patients were randomized 1:1 to duloxetine at a dose of 
30 mg orally daily for 1 week followed by 60 mg orally 
daily for 11 weeks, or to matching placebo containing 
Nu-Pareli sugar spheres. Patients were stratified based 
on prior taxane chemotherapy and baseline average pain 
score (4-6 vs 7-10). Demographic and clinical infor-
mation was collected at baseline, including height and 
weight to calculate BMI. Patients were categorized as 
those with a BMI <30 kg/m2 (nonobese) or ≥30 kg/m2 
(obese). Validated questionnaires were used to assess 
patient symptoms. The BPI-Short Form was used to 
rate average and worst pain over the prior week as well 
as interference of pain with daily activities on a scale 
from 0 to 10, and was collected at baseline and after 
2, 6, and 12 weeks of treatment.14 Three other scales 
also were used to assess patients’ symptoms at the same 
time points, including: 1) the Modified Score for the 
Assessment and Quantification of Chronic Rheumatoid 
Affections of the Hands (M-SACRAH); 2) the Western 
Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC); and 3) the Functional Assessment of 
Cancer Therapy–Endocrine Symptoms (FACT-ES) Trial 
Outcome Index.15-17 The Global Ratings of Change 
questionnaire regarding joint pain and stiffness was 
assessed at 2, 6, and 12 weeks, with scores ranging from 
-3 for “very much worse” to +3 for “very much better” 
than the prior assessment.18
Statistical Analysis
Participant characteristics at baseline were described by 
BMI category (obese vs nonobese). Differences by BMI 
were identified using chi-square tests for categorical 
measures and Student t tests for continuous measures.
The primary prespecified aim was to examine 
whether intervention effects with respect to the main 
outcome from SWOG S1202 (BPI average pain at 
12 weeks) differed between obese (BMI ≥30 kg/m2) and 
nonobese (BMI <30 kg/m2) patients. Mean scores of 
multiple patient-reported outcomes (PROs) were calcu-
lated at baseline and through 12 weeks, corresponding 
to the  intervention period, separately by treatment group 
(duloxetine vs placebo) and BMI group (<30 kg/m2 
vs ≥30 kg/m2). Multiple linear regression was used 
 adjusting for the stratification factors and the baseline 
score. In the main regression model, we tested whether 
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the interaction of BMI status and the intervention effect 
(evaluated as the product of indicator terms for interven-
tion  [duloxetine (1) vs placebo (0)] and BMI category) was 
statistically significant at the α level of .05. Secondary 
outcomes were examined in a similar fashion, including 
BPI worst pain and BPI pain interference; the Physical 
Well-Being, Functional Well-Being, and Endocrine 
Subscales of the FACT-ES; WOMAC; M-SACRAH; 
and Global Ratings in Change in joint pain and joint 
stiffness. Race also was included as a covariate in a sec-
ondary analysis of the regression models of the primary 
and secondary outcomes.
RESULTS
Patient Characteristics
Of the 299 patients enrolled in SWOG S1202, a total 
of 145 patients who were treated with duloxetine and 
144 who were treated with placebo were eligible for 
the primary analysis. All eligible patients had BMI 
 measurements available and therefore were included in 
this analysis. Of the analyzed patients, 54% were obese, 
and the median BMI was 31 kg/m2 (range, 18-76 kg/m2). 
Patient characteristics at baseline, by BMI, are pro-
vided in Table 1. All factors were well balanced with the 
exception of race: obese women were more likely to be 
black.
TABLE 1. Patient Characteristics at the Time  
of Study Entry
Characteristic
BMI <30 kg/m2
N = 133
BMI ≥30 kg/m2
N = 156 P
Age, y
<55 31 (23%) 36 (23%) .16
55-59 41 (31%) 31 (20%)
60-64 26 (20%) 39 (25%)
≥65 35 (26%) 50 (32%)
Hispanic ethnicity
No 128 (97%) 149 (96%) .52
Yes 4 (3%) 7 (4%)
Race
Black 5 (4%) 22 (14%) .02
Other 2 (2%) 2 (1%)
Asian 6 (5%) 3 (2%)
Unknown 1 (<1%) –
White 119 (89%) 129 (83%)
AI
Anastrozole 73 (55%) 96 (61%) .42
Letrozole 45 (34%) 48 (31%)
Exemestane 15 (11%) 12 (8%)
Mo receiving AI therapy 11.8 (9.0)a 12.4 (8.6)a .60
Y since menopause 12.5 (10.4)a 13.5 (9.2)a .38
Taxane chemotherapy 65 (49%) 91 (58%) .11
Baseline BPI average 
pain score
4-6 103 (77%) 117 (75%) .63
7-10 30 (23%) 39 (25%)
Treatment group
Duloxetine 67 (50%) 78 (50%) .95
Placebo 66 (50%) 78 (50%)
Abbreviations: AI, aromatase inhibitor; BMI, body mass index; BPI, Brief 
Pain Inventory.
aThe values shown in parentheses represents the standard deviations.
TABLE 2. BPI Endpoint Results by Intervention Assignment and BMI Status
Patient-Reported  
Outcomes
BMI <30 kg/m2
Pa,b
BMI ≥30 kg/m2
Pa,b Pc
Duloxetine 
N = 67
Placebo 
N = 66
Duloxetine 
N = 78
Placebo 
N = 78
Time Point Mean (SD) Mean (SD) Mean (SD) Mean (SD)
BPI average pain Baseline 5.39 (1.32) 5.50 (1.33) .46 5.65 (1.39) 5.59 (1.43) .90 .35
Wk 2 3.67 (2.22) 4.10 (2.00) .22 3.93 (2.30) 4.96 (1.73) .001 .0009
Wk 6 3.10 (2.13) 3.34 (2.16) .59 2.94 (2.13) 4.52 (1.91) <.0001 <.0001
Wk 12 2.93 (2.16) 3.16 (2.22) .75 2.92 (2.10) 3.95 (2.02) .003 .02
BPI worst pain Baseline 6.77 (1.45) 7.11 (1.60) .14 7.22 (1.56) 7.08 (1.51) .67 .25
Wk 2 4.83 (2.59) 5.38 (2.33) .30 4.64 (2.46) 6.37 (2.11) <.0001 <.0001
Wk 6 4.30 (2.43) 4.84 (2.71) .31 3.88 (2.77) 5.77 (2.44) <.0001 .0003
Wk 12 4.15 (2.80) 4.66 (2.76) .40 3.95 (2.86) 5.31 (2.64) .003 .03
BPI pain interference Baseline 4.45 (2.02) 4.92 (1.99) .12 5.05 (2.11) 4.94 (2.09) .84 .24
Wk 2 2.40 (2.16) 3.34 (2.34) .03 2.48 (2.16) 3.67 (1.83) <.0001 <.0001
Wk 6 1.78 (1.87) 2.41 (2.16) .16 2.08 (2.36) 3.58 (2.20) <.0001 <.0001
Wk 12 1.80 (2.10) 2.31 (2.17) .38 2.01 (2.18) 3.05 (2.16) .002 .005
Abbreviations: BMI, body mass index; BPI, Brief Pain Inventory; SD: standard deviation.
Decrease in score reflects less pain or pain interference.
aP values used linear regression to compare treatment groups, separately by BMI group, and were adjusted for the stratification factors of baseline pain score 
(4-6 vs 7-10) and prior taxane therapy (yes vs no). Postbaseline measures also were adjusted for baseline measures.
bBold type indicates statistical significance.
cP value tested the interaction between the treatment group and BMI group.
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Association Between BMI and Response 
to Therapy
The observed difference between the mean baseline and 
mean follow-up scores among the patients treated with 
duloxetine compared with those treated with placebo dif-
fered substantially for the obese versus nonobese cohorts 
(Table 2). In patients with a BMI <30 kg/m2, the reduc-
tion in the mean average pain score was similar between 
the duloxetine-treated and placebo-treated  patients at each 
time point during treatment. Conversely, among  patients 
with a BMI ≥30 kg/m2, the reduction in pain score 
was statistically significantly greater at all postbaseline 
time points for the patients treated with  duloxetine 
compared with those treated with placebo (Fig. 1). 
At the 12-week time point in particular, the reduction 
in the observed mean average pain score was similar 
by treatment arm for patients with a BMI <30 kg/m2 
(-2.46 points for duloxetine vs -2.34 points for placebo; 
P = .75), but differed between the duloxetine-treated 
 patients and the placebo-treated patients for patients 
with a BMI ≥30 kg/m2 (-2.73 points vs -1.64 points; 
P = .003 [P for interaction, .02]). This pattern of dif-
ferent effect sizes between obese and nonobese patients 
was even more pronounced at 2 weeks (P for interaction, 
Figure 1. Change in Brief Pain Inventory (BPI) average pain scores from baseline to follow-up by intervention and obesity status. 
P values compared the average pain scores between cohorts treated with duloxetine versus those receiving placebo by body 
mass index (BMI) cohort at each time point, and P values for interaction examined the interaction between BMI and treatment. 
A decrease in the BPI scores indicates less pain.
Duloxetine for AIMSS and Obesity Status/Henry et al
2127Cancer  June 15, 2019
.0009) and 6 weeks (P for interaction, <.0001). Given 
that obese women were more likely to be black, we also 
included race as a covariate in a secondary analysis; the 
results were very similar, with P values for interaction of 
.002, <.0001, and .02, respectively, at weeks 2, 6, and 12.
Similar findings were noted for other joint-related 
PROs assessed (Tables 2 and 3), with the BPI worst 
pain, BPI pain interference, M-SACRAH, WOMAC, 
and Functional Well-Being subscale of the FACT-ES all 
demonstrating statistically significantly more favorable 
outcomes for obese women in the duloxetine treatment 
group compared with placebo at all postbaseline time 
points, but not for nonobese women. No differences 
 between treatment cohorts or by BMI were identified for 
the Physical Well-Being subscale of the FACT-ES, and 
only a minimal difference was observed for the FACT-ES 
Endocrine Subscale. Results were similar if black race 
also was added as a covariate to the regression models 
(data not shown).
For the Global Ratings of Change, there was signifi-
cantly improved joint pain and joint stiffness in patients 
treated with duloxetine compared with placebo regard-
less of BMI at the 2-week time point. These differences 
persisted for obese patients at the 6-week time point, but 
did not persist for either group during the remainder of 
treatment.
Results were similar for all measures when the per-
centage of patients achieving a 2-point improvement in 
pain scores and other PROs was used (see Supporting 
Table 1).
TABLE 3. PRO Endpoint Results by Intervention Assignment and BMI Status
BMI <30 kg/m2 BMI ≥30 kg/m2
Pa,b PcPRO
Duloxetine 
N = 67
Placebo 
N = 66
Duloxetine 
N = 78
Placebo 
N = 78
Time 
Point Mean (SD) Mean (SD) Pa,b Mean (SD) Mean (SD)
FACT-ES Subscales
Functional Well-Being Baseline 16.95 (5.58) 16.51 (5.50) .64 15.79 (5.14) 16.26 (5.77) .66 .66
(range, 0 to 28) Wk 2 19.32 (5.42) 17.77 (6.07) .10 19.00 (5.44) 17.18 (5.45) .003 .004
Wk 6 20.25 (5.90) 19.03 (6.25) .25 19.37 (6.06) 16.17 (5.63) <.0001 <.0001
Wk 12 19.85 (6.41) 19.57 (5.69) .93 18.98 (6.28) 17.39 (5.55) .01 .03
Physical Well-Being Baseline 18.00 (5.68) 18.00 (4.87) .93 17.82 (4.24) 17.63 (4.80) .70 .98
(range, 0 to 28) Wk 2 20.49 (5.03) 21.14 (4.98) .38 20.34 (4.65) 21.20 (3.53) .13 .37
Wk 6 22.48 (4.45) 22.00 (5.21) .49 21.66 (4.75) 20.47 (3.94) .24 .12
Wk 12 22.80 (4.48) 22.25 (4.99) .34 22.10 (4.79) 21.34 (3.74) .63 .35
Endocrine Subscale Baseline 57.02 (11.06) 51.63 (12.62) .01 54.37 (10.96) 51.00 (11.38) .08 .01
(range, 0 to 76) Wk 2 63.25 (9.21) 56.69 (11.30) .004 61.10 (9.99) 57.80 (9.44) .17 .02
Wk 6 62.24 (10.76) 57.68 (11.69) .21 62.70 (9.56) 56.52 (9.36) .02 .08
Wk 12 63.52 (9.26) 58.84 (10.93) .09 63.00 (9.20) 57.10 (9.21) .02 .04
WOMAC Baseline 52.05 (17.78) 53.15 (18.22) .62 58.12 (17.21) 55.88 (17.78) .42 .15
(range, 0 to 240) Wk 2 29.54 (21.33) 38.75 (23.21) .006 32.10 (21.54) 47.01 (18.95) <.0001 <.0001
Wk 6 25.26 (19.67) 30.60 (23.17) .13 25.53 (20.12) 43.14 (21.01) <.0001 <.0001
Wk 12 24.20 (19.70) 29.36 (21.31) .13 24.12 (19.11) 39.19 (21.50) <.0001 <.0001
M-SACRAH Baseline 36.31 (23.27) 38.72 (25.04) .43 37.42 (24.36) 37.43 (21.51) .93 .91
(range, 0 to 120) Wk 2 20.11 (17.90) 28.06 (24.61) .02 17.56 (18.63) 32.62 (20.80) <.0001 <.0001
Wk 6 18.53 (18.26) 23.56 (21.39) .19 14.70 (17.01) 30.68 (20.72) <.0001 <.0001
Wk 12 18.58 (20.54) 21.37 (21.07) .51 17.28 (18.42) 27.04 (22.59) .005 .02
Global Ratings of Change in 
joint pain
Wk 2 1.36 (1.23) 0.67 (1.41) .004 1.44 (1.25) 0.61 (1.11) <.0001 <.0001
(range, -3 to +3) Wk 6 1.15 (1.35) 0.93 (1.24) .32 1.16 (1.42) 0.42 (1.47) .003 .008
Wk 12 0.69 (1.61) 0.69 (1.46) .99 0.75 (1.60) 0.63 (1.37) .52 .94
Global Ratings of Change in 
joint stiffness
Wk 2 1.31 (1.21) 0.49 (1.40) .0008 1.18 (1.36) 0.38 (0.99) .0001 <.0001
(range -3 to +3) Wk 6 0.98 (1.21) 0.77 (1.25) .28 0.94 (1.20) 0.46 (1.17) .02 .08
Wk 12 0.59 (1.49) 0.44 (1.48) .56 0.58 (1.39) 0.59 (1.24) .96 .93
Abbreviations: BMI, body mass index; FACT-ES TOI, Functional Assessment of Cancer Therapy–Endocrine Symptoms Trial Outcomes Index; M-SACRAH, 
Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands; PRO, patient-reported outcome; SD, standard devia-
tion; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
An increase in FACT-ES subscales scores reflects better well-being. Higher WOMAC scores and higher M-SACRAH scores reflect worse pain, stiffness, and 
functional limitations.
aP values used linear regression to compare treatment groups, separately by BMI group, and were adjusted for the stratification factors of baseline pain score (4-6 
vs 7-10) and prior taxane therapy (yes vs no). Postbaseline measures (except for Global Ratings of Change measures) also were adjusted for baseline measures.
bBold type indicates statistical significance.
cP value tested the interaction between the treatment group and BMI group.
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DISCUSSION
In this secondary analysis of SWOG S1202, we demon-
strated clinically and statistically significant improve-
ments in average pain, worst pain, and pain interference 
with 12 weeks of treatment with duloxetine compared 
with blinded placebo in obese patients with AIMSS. 
This is clinically relevant because obesity is a risk factor 
for the development of AI-associated arthralgias, which 
can lead to decreased persistence with AI therapy, and 
to the best of our knowledge, few effective treatment 
options exist. In contrast, nonobese patients reported a 
similar improvement in pain regardless of treatment, and 
the improvement was numerically less than in the obese 
 patients treated with duloxetine.
These findings are consistent with recently pub-
lished findings from SWOG S0927, in which patients 
with AIMSS were treated with O3-FA supplementa-
tion or placebo.13 In that exploratory analysis, obese 
patients also experienced greater improvements in pain 
with O3-FA treatment compared with placebo, whereas 
nonobese patients obtained a similar benefit from both 
O3-FA and placebo. To our knowledge, the mechanism 
underlying this effect is unclear. Both O3-FA and anti-
depressants have been shown to have anti-inflammatory 
properties, although it is not known whether there is a 
differential anti-inflammatory effect by BMI19-21; studies 
currently are ongoing to assess changes in inflammatory 
markers and response to therapy. Based on pharmacoki-
netic analyses of duloxetine, patients with higher body 
weight do not have increased exposure to duloxetine, and 
therefore it does not appear that differential metabolism 
of the drug accounts for the increased activity noted in 
obese patients.22 Analyses of predictors of placebo effects 
in studies of treatments of other conditions generally 
have not reported effects of BMI.23 One study examining 
predictors of placebo response for functional dyspepsia 
reported a lower placebo response in patients with a low 
BMI, which is the opposite finding from the 2 AIMSS 
trials.24
Is it possible that there is a difference in the etiology 
of AIMSS between patients with and without obesity? 
Several comorbidities are more common in postmeno-
pausal women with obesity, including those associated 
with chronic pain such as osteoarthritis. Obesity also is 
associated with low-grade chronic inflammation, with 
abnormal cytokine production and increased activation 
of inflammatory signaling pathways.12 There also may be 
differences in diet and exercise, or other unknown con-
founders that could contribute to differences in analgesic 
response. Unfortunately, factors that would allow for the 
additional examination of these potential mechanisms, 
including baseline pain scores at the time of AI initiation, 
diet composition, and expectations of response to study 
treatment, were not collected from enrolled patients. A 
large ongoing observational study of women initiating 
treatment with anastrozole for early-stage breast cancer, 
ECOG-ACRIN E1Z11, is prospectively collecting PROs 
and samples and potentially could be used to examine 
these mechanistic questions.
The findings of the current study suggest that in 
studies examining AI toxicity interventions, stratifica-
tion by BMI should be considered. In addition, given the 
high rate of placebo response observed in the nonobese 
patients, this also may need to be accounted for in future 
management trials, and the identification of predictors of 
placebo response may be useful.
This exploratory study had numerous strengths. 
SWOG S1202 was a large multicenter, placebo- controlled 
randomized trial in which the patient-reported symp-
toms, including pain scores, were collected prospectively. 
The inclusion criteria were broad and required moder-
ate to severe average pain at baseline, and therefore the 
results are generalizable to many patients with AI arthral-
gia. Patients were treated uniformly across study sites 
 according to the duloxetine package insert. Moreover, 
the hypothesis for this post hoc analysis was prespeci-
fied and tested at the α level of .05, thereby limiting the 
potential for false-positive findings. There also are a few 
limitations in addition to those described above, includ-
ing that the original study was not designed to examine 
differences in pain scores by BMI, and the intervention 
was limited to 12 weeks.
In the placebo-controlled SWOG S1202 trial, obese 
patients with AIMSS derived more analgesic benefit 
from duloxetine compared with nonobese patients, and 
compared with obese patients treated with placebo. In 
addition, nonobese patients experienced similar analge-
sic benefits from either duloxetine or placebo. Additional 
studies are warranted to determine the biologic basis for 
these findings, such as a different mechanism underlying 
the development of AIMSS or pain expression in patients 
with obesity, or other confounding variables related to 
analgesic response to duloxetine compared with placebo.
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